Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 63 of 82 for:    acne AND Acne Scars

10 600 nm Ablative Fractional Laser Treatment of Scars: a Prospective Single Blinded Within Patient Controlled Randomized Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01639105
Recruitment Status : Unknown
Verified December 2014 by University Hospital, Ghent.
Recruitment status was:  Recruiting
First Posted : July 12, 2012
Last Update Posted : December 5, 2014
Sponsor:
Information provided by (Responsible Party):
University Hospital, Ghent

Brief Summary:

Rationale The cosmetic aspect of scars is a frequent reason for consultation. It plays an important role in patient satisfaction and self-image. Several treatment modalities are proposed for scars with variable success.

Ablative fractional laser treatment is a rather new concept. Many microscopic small laser beams target the dermis in a grid pattern. The vertical columns of skin hit by the laser beams heat up. This thermal effect stimulates the wound healing and potentially leads to a remodeling of the skin structure.

Ablative fractional laser treatment has been used successfully for treatment of pigment changes, wrinkles, acne scars and thermal burn wounds. It has been reported that CO2 ablative fractional laser treatment has a positive clinical effect on various types of scars however this has not been proven yet in a prospective randomized trial. The low morbidity of the treatment and the lack of convincing adapted treatment modalities for various types of scars make this treatment attractive.

That's why the investigators aim with this randomized study to evaluate the clinical effect and the safety of 10 600 nm ablative fractional laser therapy for patients with recent scars due to surgical interventions.

Goal Evaluate the efficacy of three 10 600 nm ablative fractional laser treatments for the above mentioned scars, three months after the last laser treatment, with a prospective randomized intra-patient controlled study.

Study design Prospective single blinded randomized intra-patient controlled study. The study comprises 4 study visits.

Study population The population consists of one group of patients with scars after recent surgical operations. The patients must meet the inclusion and exclusion criteria described in the protocol.

Method The scar will be divided in two equal halves. The two halves will be randomized. One part will not be treated. The other part will undergo three times the 10 600 nm ablative laser therapy with 4 weeks interval between the treatments. The efficacy of the treatment will be evaluated three months after the last treatment with objective and subjective parameters.

Most important study endpoints:

  • Evaluation of the efficacy of the treatment. A blinded clinical scar evaluation will be done of the treated and untreated parts with the POSAS scar scale, by a study collaborator and by the patient himself, on a category scale of 0 to 10 (0 = normal skin, 10 = worst scar imaginable), before start and twelve weeks after the last treatment.
  • Evaluation of the pain related to the treatment. The pain will be scored by the patient with the VAS category scale from 0 to 10 (0 = no pain, 10 = worst pain ever).
  • Evaluation of the side effects of the treatment. A standardized form will be used.
  • Evaluation of the global patient satisfaction regarding the treatment.
  • Clinical photos, before start and twelve weeks after the last treatment.

Condition or disease Intervention/treatment Phase
Scars After Surgical Intervention Procedure: Laser treatment Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: 10 600 nm Ablative Fractional Laser Treatment of Scars: a Prospective Single Blinded Within Patient Controlled Randomized Trial
Study Start Date : February 2013
Estimated Primary Completion Date : June 2015
Estimated Study Completion Date : June 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Scars

Arm Intervention/treatment
Experimental: treated half of the scar Procedure: Laser treatment
10 600 NM ABLATIEVE FRACTIONATED LASER

No Intervention: untreated half of the scar



Primary Outcome Measures :
  1. Clinical aspect of the scar 3 months after the last laser treatment [ Time Frame: 3 months after the last laser treatment ]
    POSAS scar scale


Secondary Outcome Measures :
  1. Pain [ Time Frame: 3 months after the last laser treatment ]
    VAS scale for pain measurement

  2. Number and severity of side effects [ Time Frame: 3 months after the last laser treatment ]
    Will be measured by clinical photographs

  3. satisfaction [ Time Frame: 3 months after the last laser treatment ]
    Will be measured with the standardized satisfaction scale



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Scars caused by surgical intervention, that are 2 months old

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01639105


Contacts
Layout table for location contacts
Contact: Barbara Boone, MD, PhD barbara.boone@ugent.be

Locations
Layout table for location information
Belgium
Ghent University Hospital Recruiting
Ghent, Belgium
Contact: Barbara Boone, MD, PhD         
Principal Investigator: Barbara Boone, MD, PhD         
Sponsors and Collaborators
University Hospital, Ghent
Investigators
Layout table for investigator information
Principal Investigator: Barbara Boone, MD, PhD University Hospital, Ghent

Layout table for additonal information
Responsible Party: University Hospital, Ghent
ClinicalTrials.gov Identifier: NCT01639105     History of Changes
Other Study ID Numbers: 2012/395
First Posted: July 12, 2012    Key Record Dates
Last Update Posted: December 5, 2014
Last Verified: December 2014